DK

David Kirske

Chief Financial Officer

X4 Pharmaceuticals

X4 Pharmaceuticals Pipeline

DrugIndicationPhase
XOLREMDI (mavorixafor)WHIM SyndromeApproved
MavorixaforChronic Neutropenic DisordersPhase 3